Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Kristl

Neurology Mishawaka, IN Medical Doctor

NPI 1811941768 CMS profile 309590

1710 E Day Rd, Mishawaka, IN 46545

Open in the dashboard

General payments

$35,498

1,789 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Kristl of Mishawaka, IN is reported in the CMS Open Payments database as having received $35,498 across 1,789 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,525 300
2024 General $5,692 286
2023 General $6,252 293
2022 General $5,011 260
2021 General $4,868 230
2020 General $2,757 164
2019 General $4,393 256

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Kristl
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Kevin Kristl were reported at $6,525. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Kevin Kristl Neurology median Middle half National median
2019 $4,393 $474 $118–$2,177 $163
2020 $2,757 $367 $82–$2,309 $114
2021 $4,868 $438 $104–$2,547 $132
2022 $5,011 $442 $103–$2,388 $149
2023 $6,252 $464 $119–$2,312 $160
2024 $5,692 $468 $119–$2,323 $164
2025 $6,525 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,305 211 payments
  2. Teva Pharmaceuticals USA, Inc. $1,962 102 payments
  3. Novartis Pharmaceuticals Corporation $1,579 110 payments
  4. Biogen, Inc. $1,563 92 payments
  5. LivaNova USA, Inc. $1,487 50 payments
  6. UCB, Inc. $1,482 110 payments
  7. ACADIA Pharmaceuticals Inc $1,242 56 payments
  8. Neurocrine Biosciences, Inc. $1,229 39 payments
  9. EMD Serono, Inc. $1,195 60 payments
  10. CSL Behring $934 32 payments
  11. Other $19,521 927 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $34,344 1,772 payments
  2. Education $854 12 payments
  3. Travel and Lodging $221 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $80 4 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $2,326 151 payments
  2. QULIPTA $1,920 118 payments
  3. VNS Therapy $1,144 32 payments
  4. NURTEC ODT $997 47 payments
  5. TYSABRI $991 62 payments
  6. Hizentra $934 32 payments
  7. NUPLAZID $808 33 payments
  8. Briviact $763 62 payments
  9. FYCOMPA $660 30 payments
  10. REXULTI $636 18 payments
  11. Other $26,186 1,409 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 136 drugs

Part D claims

9,274

Median for Neurology: 833

Drug cost

$5,373,808

Median for Neurology: $202,670

Branded share of claims

38.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 49 $467,497
Ingrezza Valbenazine Tosylate Brand 57 $462,252
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 29 $401,474
Vumerity Diroximel Fumarate Brand 41 $365,444
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 28 $261,688
Kesimpta Pen Ofatumumab Brand 27 $229,054
Nuplazid Pimavanserin Tartrate Brand 46 $219,845
Avonex Pen (4 Pack) Interferon Beta-1a Brand 26 $206,451
Briviact Brivaracetam Brand 137 $201,893
Aptiom Eslicarbazepine Acetate Brand 115 $192,932

The 10 drugs with the highest cost, of 136 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$548,412

Of which drugs: $437,775

Medicare patients

423

Average age 68

Services billed

31,159

230 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 45%
Depression 35%
Diabetes 27%
Ischemic heart disease 18%
Chronic kidney disease 18%
Alzheimer's or dementia 18%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 58 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Apokyn
$377 — —
QULIPTA
$338 136 —
UBRELVY
$318 141 —
KESIMPTA
$286 27 —
NUPLAZID
$277 46 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 58 with Patron

Records

1,789 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record